title: T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up.
abstract: The use of allogeneic BMT in patients with relapsed non-Hodgkin lymphoma (NHL) offers the advantage of tumor-free bone marrow and possibly a 'graft-versus-lymphoma effect' which may decrease the risk of recurrence. However, allogeneic BMT also poses an increased risk of death due to graft-versus-host disease (GVHD) which can be ameliorated by T cell depletion. We performed a retrospective review of 37 patients who underwent T cell-depleted allogeneic BMT for aggressive and indolent NHL between 1988 and 1996. Polymerase chain reaction (PCR) was used to identify indolent NHL patients with the BCL2/IgH translocation which served as a marker of residual disease. Sixteen of 37 patients (44%) are alive and progression-free with a median follow-up of 4.4 years (range 1-10.3). The incidence of grade 2-4 acute GVHD was 36% and extensive chronic GVHD developed in 12%. Patients with aggressive NHL have an overall PFS of 33% (12-54%); those with chemotherapy-resistant and sensitive disease have PFS of 17% (0-47%), and 40% (15-65%) respectively at 5 years. Patients with indolent histologies have overall PFS of 62% (37-86%); those with chemotherapy-resistant and sensitive disease have PFS of 55% (25-85%) and 80% (45-100%) respectively at 5 years. Eight patients with indolent disease had a BCL2/IgH translocation detectable by PCR. Five of these eight patients remain alive and progression free at a median of 6.5 years after BMT (range 2.1-7.4 years), four of whom remain PCR positive from 1.7 to 2.9 years after transplantation. We conclude that T cell-depleted allogeneic BMT poses a low risk for death due to GVHD, and should be considered for patients with relapsed and refractory indolent NHL.
authors.affiliation: Department of Medicine, Medical College of Wisconsin, Milwaukee, USA.
authors.forename: M
authors.initials: M
authors.lastname: Juckett
authors.forename: P
authors.initials: P
authors.lastname: Rowlings
authors.forename: M
authors.initials: M
authors.lastname: Hessner
authors.forename: C
authors.initials: C
authors.lastname: Keever-Taylor
authors.forename: W
authors.initials: W
authors.lastname: Burns
authors.forename: B
authors.initials: B
authors.lastname: Camitta
authors.forename: J
authors.initials: J
authors.lastname: Casper
authors.forename: W R
authors.initials: WR
authors.lastname: Drobyski
authors.forename: G
authors.initials: G
authors.lastname: Hanson
authors.forename: M
authors.initials: M
authors.lastname: Horowitz
authors.forename: C
authors.initials: C
authors.lastname: Lawton
authors.forename: J
authors.initials: J
authors.lastname: Margolis
authors.forename: D
authors.initials: D
authors.lastname: Peitryga
authors.forename: D
authors.initials: D
authors.lastname: Vesole
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000379:methods*; D002648:Child; D002883:Chromosomes, Human, Pair 14 / Q000235:genetics; D002887:Chromosomes, Human, Pair 18 / Q000235:genetics; D005260:Female; D019254:Genes, bcl-2; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D008212:Lymphocyte Depletion; D008228:Lymphoma, Non-Hodgkin / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012189:Retrospective Studies; D015996:Survival Rate; D013601:T-Lymphocytes; D014178:Translocation, Genetic; D014184:Transplantation, Homologous
chemical_list: D007143:Immunoglobulin Heavy Chains